Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Prostatic Neoplasms 4Urinary Bladder Neoplasms 3Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Neoplasm Metastasis 1

Interventions

osimertinib 2Trastuzumab 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Fulvestrant 2ulixertinib 1tucatinib 1trastuzumab biosimilar HLX02 1trametinib 1seribantumab 1sapanisertib 1relatlimab 1pertuzumab 1pembrolizumab 1palbociclib 1omipalisib 1larotrectinib 1ipatasertib 1ferumoxtran-10 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1cobimetinib 1cemiplimab 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Surveys and Questionnaires 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Neoplasms × ferumoxtran-10 × Genitourinary × Clear all
NCT00188695 2022-10-07

Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

University Health Network, Toronto

Phase 1/2 Completed
61 enrolled
GenitourinaryGynecologic

Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Prostatic Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡